JP2020523409A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523409A5
JP2020523409A5 JP2020517769A JP2020517769A JP2020523409A5 JP 2020523409 A5 JP2020523409 A5 JP 2020523409A5 JP 2020517769 A JP2020517769 A JP 2020517769A JP 2020517769 A JP2020517769 A JP 2020517769A JP 2020523409 A5 JP2020523409 A5 JP 2020523409A5
Authority
JP
Japan
Prior art keywords
pge2
anesthetic
composition
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020517769A
Other languages
English (en)
Japanese (ja)
Other versions
JP7372911B2 (ja
JP2020523409A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/036727 external-priority patent/WO2018227134A1/en
Publication of JP2020523409A publication Critical patent/JP2020523409A/ja
Publication of JP2020523409A5 publication Critical patent/JP2020523409A5/ja
Priority to JP2023123301A priority Critical patent/JP2023139260A/ja
Application granted granted Critical
Publication of JP7372911B2 publication Critical patent/JP7372911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020517769A 2017-06-09 2018-06-08 筋肉の状態を予防または治療するための組成物および方法 Active JP7372911B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023123301A JP2023139260A (ja) 2017-06-09 2023-07-28 筋肉の状態を予防または治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517758P 2017-06-09 2017-06-09
US62/517,758 2017-06-09
PCT/US2018/036727 WO2018227134A1 (en) 2017-06-09 2018-06-08 Compositions and methods for preventing or treating muscle conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023123301A Division JP2023139260A (ja) 2017-06-09 2023-07-28 筋肉の状態を予防または治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020523409A JP2020523409A (ja) 2020-08-06
JP2020523409A5 true JP2020523409A5 (enExample) 2021-07-26
JP7372911B2 JP7372911B2 (ja) 2023-11-01

Family

ID=64566381

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517769A Active JP7372911B2 (ja) 2017-06-09 2018-06-08 筋肉の状態を予防または治療するための組成物および方法
JP2023123301A Pending JP2023139260A (ja) 2017-06-09 2023-07-28 筋肉の状態を予防または治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023123301A Pending JP2023139260A (ja) 2017-06-09 2023-07-28 筋肉の状態を予防または治療するための組成物および方法

Country Status (9)

Country Link
US (4) US20190167695A1 (enExample)
EP (1) EP3634424A4 (enExample)
JP (2) JP7372911B2 (enExample)
KR (1) KR102698911B1 (enExample)
CN (1) CN111212648B (enExample)
AU (1) AU2018280264B2 (enExample)
CA (1) CA3065945A1 (enExample)
GB (1) GB2578539B (enExample)
WO (2) WO2018227134A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4538365A3 (en) 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
GB2578539B (en) 2017-06-09 2022-08-10 Univ Leland Stanford Junior Compositions and methods for preventing or treating muscle conditions
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
GB2599292A (en) * 2019-06-11 2022-03-30 Univ Leland Stanford Junior Methods of rejuvenating aged tissue by inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH)
WO2021011747A1 (en) * 2019-07-16 2021-01-21 Children’S National Medical Center Method for treatment of muscular dystrophy
JP7677983B2 (ja) 2020-01-23 2025-05-15 マイオフォルテ セラピューティクス，インク． Ｐｇｄｈ阻害剤、およびその作製と使用の方法
AU2021224268A1 (en) 2020-02-21 2022-09-15 Case Western Reserve University Compositions and methods for treating renal injury
US20230187041A1 (en) * 2020-05-08 2023-06-15 Intime Biotech Llc Real-time method of bio big data automatic collection for personalized lifespan prediction
EP4228650A4 (en) * 2020-10-15 2024-12-18 Myoforte Therapeutics Inc. INHALATED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF
CN117377668A (zh) * 2020-10-15 2024-01-09 迈欧伏特治疗公司 Pgdh抑制剂的吸入制剂及其使用方法
US20240000758A1 (en) * 2020-10-23 2024-01-04 The Board Of Trustees Of The Leland Stanford Junior University Elevation of mitochondrial biogenesis and function by inhibition of prostaglandin degrading enzyme 15-pgdh
JP7501333B2 (ja) * 2020-12-07 2024-06-18 コニカミノルタ株式会社 超音波診断装置、超音波診断装置の制御方法、及び、超音波診断装置の制御プログラム
JP2023552832A (ja) * 2020-12-09 2023-12-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 関節の構造および機能を改善するためのプロスタグランジン分解酵素１５－ｐｇｄｈの阻害法
CN113327235B (zh) * 2021-06-04 2022-07-01 杭州健培科技有限公司 基于ct影像肌少症评估的图像处理方法和装置
CN114107272B (zh) * 2021-12-15 2022-06-24 徐州医科大学 mPGES-2作为靶点在开发或筛选或制备用于预防和/或治疗衰老疾病的药物中的应用
US12558549B2 (en) 2022-10-28 2026-02-24 Medtronic, Inc. Lead based measurements for tongue movement determination
CN117142939B (zh) * 2023-10-30 2024-01-16 成都中医药大学 一种倍半萜化合物及其制备方法和用途及其制备的药物
CN117473328B (zh) * 2023-12-26 2024-03-15 南京麦豆健康科技有限公司 一种基于大数据的阴道松弛评估训练系统及方法
CN118351102B (zh) * 2024-05-06 2024-11-19 上海交通大学医学院附属瑞金医院 基于脑白质磁共振信号强度的图像处理方法和系统
CN119331890B (zh) * 2024-12-24 2025-03-07 中国农业科学院蜜蜂研究所 基因15-pgdh在调控蜜蜂工蜂体重、体长中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927213A (en) 1973-07-10 1975-12-16 American Home Prod Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US5143842A (en) 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
WO1991012329A2 (en) 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5833978A (en) 1995-03-16 1998-11-10 Universite Laval Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success
US5599561A (en) * 1995-08-04 1997-02-04 Gonzalez, Jr.; Angel Method of making poultice
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US6410591B1 (en) 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
JP4273407B2 (ja) 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
HUE029417T2 (en) * 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
US6841573B2 (en) 2002-11-27 2005-01-11 Molecular Nutrition Use of arachidonic acid as a method of increasing skeletal muscle mass
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
AR059430A1 (es) 2006-02-09 2008-04-09 Schering Corp Novedosas combinaciones y metodos de inhibidores del vhc
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
CA2652040C (en) 2006-05-17 2015-07-21 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
WO2008157753A1 (en) 2007-06-21 2008-12-24 Sma Foundation Methods of treatment for spinal muscular atrophy
US7632848B1 (en) * 2007-10-04 2009-12-15 Alan Brown Scott Medical treatment of muscles by exposure to anesthetic drugs
BRPI0819707A2 (pt) 2007-11-29 2015-06-16 Allergan Inc Ciclopentanos substituídas tendo atividade de prostaglandina
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
CN102057037B (zh) 2008-04-11 2014-06-18 学校法人庆应义塾 平滑肌干细胞的分离方法
US20110004589A1 (en) 2009-07-06 2011-01-06 Rockwell Automation Technologies, Inc. Diagnostics in a distributed directory system
US8193220B1 (en) 2009-08-20 2012-06-05 Alan Brown Scott Method of changing muscle lengths with anesthetic drugs
EP2637702A4 (en) 2010-11-11 2014-11-26 Univ Miami METHODS, COMPOSITIONS, CELLS AND KITS FOR TREATING ISCHEMIC INJURIES
US9782417B2 (en) 2011-06-16 2017-10-10 Presidents And Fellows Of Harvard College Methods of increasing satellite cell proliferation with kinase inhibitors
WO2012174537A2 (en) 2011-06-16 2012-12-20 President And Fellows Of Harvard College Small molecule screening for mouse satellite cell proliferation
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
CA2870666A1 (en) * 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
KR101244964B1 (ko) 2012-05-30 2013-03-18 조선대학교산학협력단 15-히드록시프로스타글란딘 디히드로게나제 및 ｐｇｅ2 활성을 조절하는 황칠나무 추출물의 용도
US20130331389A1 (en) 2012-06-11 2013-12-12 National Cheng Kung University Methods and Compositions for Cardiomyocyte Replenishment by Endogenous and Progenitor Stem Cells
US9154479B1 (en) 2012-09-14 2015-10-06 Amazon Technologies, Inc. Secure proxy
CA2927730A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
EP4538365A3 (en) 2016-03-04 2025-07-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin e2
GB2578539B (en) 2017-06-09 2022-08-10 Univ Leland Stanford Junior Compositions and methods for preventing or treating muscle conditions

Similar Documents

Publication Publication Date Title
JP2023139260A5 (enExample)
GB2578539A (en) Compositions and methods for preventing or treating muscle conditions
Tsai et al. Effects of a single session of prolonged muscle stretch on spastic muscle of stroke patients
CN1310644C (zh) 药物组合产品及其在治疗胃肠疾病中的应用
CN1461216A (zh) 用作治疗有关支气管收缩的机能障碍的药物的化合物
RU2017133612A (ru) Ацилированный аналог глюкагона
WO2022120289A1 (en) Restoration of motor function post-neurological injury using psychedelics
Manigandan et al. Effect of electrical stimulation to long head of biceps in reducing gleno humeral subluxation after stroke
CN1312717A (zh) 光学纯度(+)—降西沙必利对治疗呼吸暂停、贪食症和其它疾病的用途
JP2020512364A (ja) 筋ジストロフィーの処置方法において使用するためのニンテダニブ
US20070060655A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
CN1729004A (zh) 酯组合局部麻醉剂
KR20230081687A (ko) 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
Ganu et al. Effect of retrowalking on pain, functional disability and functional mobility in patients with chronic knee osteoarthritis
CN111320635A (zh) 用于治疗骨关节炎的化合物
Attia et al. Effect of manual pressure release and scapular stabilization exercises on myofascial pain syndrome following neck dissection surgery
CN101076328A (zh) 用于睡眠障碍的预防或治疗剂
HK40029600A (en) Compositions and methods for preventing or treating muscle conditions
IL186373A (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
US7622505B2 (en) Association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it
Dauriat et al. Acute respiratory failure due to diaphragmatic weakness revealing a polymyositis
Nabil Comparing Effect of Strengthening Exercises Versus Faradic Stimulation in Knee Osteoarthritis: A Pilot Study
Ono et al. The effect of ROM exercise on rats with denervation and joint contracture
Sarkar et al. Comparative study between dexmedetomidine and dexamethasone as an adjuvant to levobupivacaine for supraclavicular brachial plexus block in patients undergoing upper limb surgeries
Alekseev et al. The influence of osteopathic correction on the restoration of the functions of the ankle joint with partial damage of its ligaments